STERIS plc (STE) Aandelenanalyse

Bedrijfsoverzicht

STERIS plc is a global provider of infection prevention products and services, operating through three distinct segments that cater to healthcare, sterilization technologies, and life sciences sectors. The company's primary focus lies in delivering cleaning chemistries, sterility assurance products, and automated endoscope reprocessing systems, alongside applied sterilization technologies to hospitals and other medical facilities. This entity operates within the Healthcare sector, specifically classified under the Medical Devices industry, which positions it as a critical supplier for maintaining hygiene standards in medical environments. With a market capitalization of $21.85B and annual revenue reaching $5.83B, the company demonstrates significant scale supported by a workforce of 17787 employees. These valuation and revenue figures indicate that STERIS holds a substantial position in the market, reflecting the high demand for infection control solutions and its established footprint in the medical device landscape.

Financiële gezondheid

The company reported total revenue of $5.83B over the trailing twelve months, generating net income of $708.52M and EBITDA of $1.57B. The substantial gap between the $5.83B revenue and the $708.52M net income reveals a cost structure that incurs significant operating expenses, taxes, and interest before arriving at the final profit, which is typical for capital-intensive manufacturing and service-oriented businesses. Free cash flow stands at $870.70M, a metric that highlights the company's robust financial flexibility to fund capital expenditures, pursue strategic acquisitions, or manage operational cash needs without relying solely on external financing. Operating margins sit at 18.5%, gross margins are recorded at 44.3%, and profit margins reach 12.1%, indicating efficient cost management relative to sales while maintaining healthy profitability across the value chain. Regarding liquidity and leverage, the company holds $423.70M in cash against $2.05B in total debt, resulting in a debt-to-equity ratio of 28.65, which suggests a leveraged balance sheet where debt significantly outweighs equity. The current ratio of 2.48 indicates strong short-term liquidity, providing ample ability to cover current liabilities with available assets. Return on equity is measured at 10.5% while return on assets stands at 6.6%, metrics that collectively reveal the effectiveness of management in generating returns on shareholder investments and utilizing the company's asset base productively.

Waarderingsbeoordeling

The trailing twelve-month P/E ratio is 31.04, while the forward P/E ratio is 20.09, implying that the market expects earnings growth in the future that would justify a lower multiple on upcoming profits compared to historical performance. The price-to-book ratio is 3.05, indicating that the market values the company at a significant premium over its net book value, likely reflecting intangible assets, brand strength, or growth prospects not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 3.75 and the EV/EBITDA of 14.90 suggest how investors are pricing the company's revenue generation and cash flow capabilities relative to its enterprise value. The stock has traded between a 52-week low of $209.98 and a 52-week high of $269.44, placing the current trading range within this historical volatility band and requiring calculation of the specific percentage distance from these extremes to gauge relative positioning. The beta of 1.07 signifies that the stock's price volatility moves slightly more than the broader market, suggesting a moderate level of systemic risk correlated with general market fluctuations.

Growth & Income

Revenue growth stands at 9.2% year-over-year, while earnings growth reaches 12.1% year-over-year, indicating that the company's profitability is expanding at a faster pace than its top line, which often points to operational leverage or pricing power. The company pays a dividend with a yield of 1.1% and maintains a payout ratio of 33.5%, a level that appears sustainable given the strong earnings growth and healthy free cash flow generation. The relatively low payout ratio leaves a significant portion of earnings available for reinvestment into research, development, or capacity expansion rather than being distributed entirely to shareholders. The overall growth and income profile reflects a mature yet growing business that balances returning capital to investors via dividends with the capacity to fund internal expansion and sustain double-digit earnings growth.